ParkerVision, Inc. (PRKR) Appeal Dismissed; Case Remanded to District Court

ParkerVision's appeal was dismissed, and its patent case against Qualcomm was sent back to Florida district court. The company seeks $440M in damages for transmitter claims, with a jury trial to proceed.

Original reporting
Published Oct 1, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ParkerVision, Inc. (PRKR) Appeal Dismissed; Case Remanded to District Court — source image
Decision brief

The 30-second read

$PRKRBearishMed
01

Why it matters

The procedural reset moves the case back to trial, extending the timeline and preserving exposure to a large damages claim.

02

Market read

Legal update likely to pressure PRKR shares pending trial outcome.

03

What to watch

Potential settlement negotiations could mitigate downside.

Relevance 7/10Novelty 7/10Timing: immediate today

Background

ParkerVision is engaged in a long‑running patent dispute with Qualcomm over transmitter technology.

Company-level read

Ticker impact

$PRKRBearishHigh confidence
Context

Federal Circuit dismissed ParkerVision's appeal and remanded the Qualcomm patent case, preserving a $440M damages ask.

Expected impact

likely downward pressure as investors price in the procedural setback

Evidence & confidence

Dismissal removes a potential win and keeps a large damages claim pending, increasing risk.

Market effects

May affect other small‑cap IP‑focused firms as the case proceeds to trial.

Limited to U.S. micro‑cap market.

Low global relevance.

Counterpoint

If the jury awards the full $440M, the stock could rally despite the appeal loss.

Key entities

  • ParkerVision, Inc.

    Plaintiff in the Qualcomm patent lawsuit.

  • Qualcomm

    Defendant in the patent dispute.

Related articles

$PRKRLow

ParkerVision Reports Third Quarter 2026 Results

PARKERVISION INC (PRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ParkerVision Reports Third Quarter 2026 Results JACKSONVILLE , Fla., November 10, 2026 – ParkerVision, Inc. (OTCQB: PRKR) (“ParkerVision” or the "Company"), a developer and marketer of technologies and products for wireless applications, today announced results for t

$PRKRMed

ParkerVision Reports Second Quarter 2026 Results

PARKERVISION INC (PRKR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ParkerVision Reports Second Quarter 2026 Results JACKSONVILLE , Fla., August 6, 2026 – ParkerVision, Inc. (OTCQB: PRKR) (“ParkerVision” or the "Company"), a developer and marketer of technologies and products for wireless applications, today announced results for the

$CAPRHighAI 8/10

CAPR Stock Rallies After-Hours As Capricor Reaffirms Deramiocel Confidence Ahead Of Nov. 22 Decision; Says Application In Final Review

Capricor (CAPR) stock rose after-hours as the company reaffirmed confidence in its Deramiocel treatment ahead of a November 22 decision. The HOPE-3 trial met its primary endpoint, showing a 1.1-point improvement in upper limb function. Capricor reported a Q3 net loss of $42.7 million and $198.5 million in cash reserves. Retail sentiment on StockTwits was extremely bullish, with mixed opinions on approval odds. CAPR stock is down 69% year-to-date.